Fate Therapeutics Submits IND Application for the Clinical...

Fate Therapeutics, Inc. , a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that it has submitted an investigational new drug application to the U.S. Food and Drug Administration for the clinical development of PROHEMA in pediatric patients with inherited ... (more)

http://ift.tt/1r7KIbG